Welcome to CIDeRplus

Field	Query

	Field	Term

General Information:

Id:	7,515
Diseases:	Alzheimer disease - [OMIM]
Organism:	Homo sapiens
Tissue/Cell line:	BTO:0000131 blood plasma
Publication type:	article
Reference:	Song F et al.(2012) Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals PLoS One 7 [PMID: 22701550]

Interaction Information:

Comment	664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio.
Formal Description Interaction-ID: 74138	phenotype mild cognitive impairment decreases_quantity of gene/protein APOA1 in plasma; in a group of Australian patients (mean age 78)

Comment	664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio.
Formal Description Interaction-ID: 74139	phenotype mild cognitive impairment decreases_quantity of gene/protein APOA2 in plasma; in a group of Australian patients (mean age 78)

Comment	664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio.
Formal Description Interaction-ID: 74140	phenotype mild cognitive impairment decreases_quantity of gene/protein APOH in plasma; in a group of Australian patients (mean age 78)
Drugbank entries	Show/Hide entries for APOH
Drugbank DB02944	Alpha-D-Mannose not specified APOH
Drugbank DB02944	Alpha-D-Mannose not specified APOH

Comment	664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio.
Formal Description Interaction-ID: 74141	phenotype mild cognitive impairment increases_quantity of gene/protein APOE in plasma; in a group of Australian patients (mean age 78)
Drugbank entries	Show/Hide entries for APOE
Drugbank DB00062	Human Serum Albumin not specified APOE
Drugbank DB00064	Serum albumin iodonated not specified APOE
Drugbank DB00062	Human Serum Albumin not specified APOE
Drugbank DB00064	Serum albumin iodonated not specified APOE

Comment	664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio.
Formal Description Interaction-ID: 74142	phenotype mild cognitive impairment increases_quantity of gene/protein CLU in plasma; in a group of Australian patients (mean age 78)

Comment	664 subjects (257 with Mild Cognitive Impairment [MCI] and 407 with normal cognition), mean age 78 years, from the Sydney Memory and Aging Study (MAS) were followed up over two years. Plasma apolipoprotein levels at baseline (Wave 1) were measured using a multiplex bead fluorescence immunoassay technique. At Wave 1, MCI subjects had lower levels of ApoA1, ApoA2 and ApoH, and higher levels of ApoE and ApoJ, and a higher ApoB/ApoA1 ratio.
Formal Description Interaction-ID: 74143	phenotype mild cognitive impairment increases_quantity of phenotype ApoB/ApoA1 ratio in plasma; in a group of Australian patients (mean age 78)

Comment	Carriers of the apolipoprotein E epsilon4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB.
Formal Description Interaction-ID: 74144	gene/protein mutant APOE (isoform E4) decreases_quantity of gene/protein APOE in plasma; in a group of APOE4 alelle carrier from Australia
Drugbank entries	Show/Hide entries for APOE
Drugbank DB00062	Human Serum Albumin not specified APOE
Drugbank DB00064	Serum albumin iodonated not specified APOE
Drugbank DB00062	Human Serum Albumin not specified APOE
Drugbank DB00064	Serum albumin iodonated not specified APOE

Comment	Carriers of the apolipoprotein E epsilon4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB.
Formal Description Interaction-ID: 74145	gene/protein mutant APOE (isoform E4) decreases_quantity of gene/protein APOC3 in plasma; in a group of APOE4 alelle carrier from Australia

Comment	Carriers of the apolipoprotein E epsilon4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB.
Formal Description Interaction-ID: 74146	gene/protein mutant APOE (isoform E4) decreases_quantity of gene/protein APOH in plasma; in a group of APOE4 alelle carrier from Australia
Drugbank entries	Show/Hide entries for APOH
Drugbank DB02944	Alpha-D-Mannose not specified APOH
Drugbank DB02944	Alpha-D-Mannose not specified APOH

Comment	Carriers of the apolipoprotein E epsilon4 allele had significantly lower levels of plasma ApoE, ApoC3 and ApoH and a significantly higher level of ApoB.
Formal Description Interaction-ID: 74147	gene/protein mutant APOE (isoform E4) increases_quantity of gene/protein APOB in plasma; in a group of APOE4 alelle carrier from Australia

Comment	Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels.
Formal Description Interaction-ID: 74148	gene/protein APOH affects_activity of phenotype global cognitive score in a group of Australian patients (mean age 78)
Drugbank entries	Show/Hide entries for APOH
Drugbank DB02944	Alpha-D-Mannose not specified APOH
Drugbank DB02944	Alpha-D-Mannose not specified APOH

Comment	Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels.
Formal Description Interaction-ID: 74149	gene/protein CLU affects_activity of phenotype global cognitive score in a group of Australian patients (mean age 78)

Comment	Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels.
Formal Description Interaction-ID: 74150	phenotype decreased level of APOH increases_activity of phenotype global cognitive score in a group of Australian patients (mean age 78)

Comment	Global cognitive scores were correlated positively with ApoH and negatively with ApoJ levels.
Formal Description Interaction-ID: 74151	phenotype increased level of CLU decreases_activity of phenotype global cognitive score in a group of Australian patients (mean age 78)

Comment	Wave 1 apolipoprotein levels were correlated with grey matter and CSF volume. ApoC3, ApoE and ApoJ were negatively correlated with grey matter volume and positively correlated with CSF volume.
Formal Description Interaction-ID: 74152	phenotype increased level of APOC3 decreases_quantity of tissue/cell line cerebral gray matter in a group of Australian patients (mean age 78)

Comment	Wave 1 apolipoprotein levels were correlated with grey matter and CSF volume. ApoC3, ApoE and ApoJ were negatively correlated with grey matter volume and positively correlated with CSF volume.
Formal Description Interaction-ID: 74155	phenotype increased level of APOE decreases_quantity of tissue/cell line cerebral gray matter in a group of Australian patients (mean age 78)

Comment	Wave 1 apolipoprotein levels were correlated with grey matter and CSF volume. ApoC3, ApoE and ApoJ were negatively correlated with grey matter volume and positively correlated with CSF volume.
Formal Description Interaction-ID: 74156	phenotype increased level of CLU decreases_quantity of tissue/cell line cerebral gray matter in a group of Australian patients (mean age 78)

Comment	Wave 1 apolipoprotein levels were correlated with grey matter and CSF volume. ApoC3, ApoE and ApoJ were negatively correlated with grey matter volume and positively correlated with CSF volume.
Formal Description Interaction-ID: 74157	phenotype increased level of APOC3 increases_quantity of tissue/cell line cerebrospinal fluid in a group of Australian patients (mean age 78)

Comment	Wave 1 apolipoprotein levels were correlated with grey matter and CSF volume. ApoC3, ApoE and ApoJ were negatively correlated with grey matter volume and positively correlated with CSF volume.
Formal Description Interaction-ID: 74158	phenotype increased level of APOE increases_quantity of tissue/cell line cerebrospinal fluid in a group of Australian patients (mean age 78)

Comment	Wave 1 apolipoprotein levels were correlated with grey matter and CSF volume. ApoC3, ApoE and ApoJ were negatively correlated with grey matter volume and positively correlated with CSF volume.
Formal Description Interaction-ID: 74159	phenotype increased level of CLU increases_quantity of tissue/cell line cerebrospinal fluid in a group of Australian patients (mean age 78)

Comment	The ApoB/ApoA1 ratio was also negatively correlated with hippocampal volume.
Formal Description Interaction-ID: 74160	phenotype increased level of ApoB/ApoA1 ratio decreases_quantity of tissue/cell line hippocampus in a group of Australian patients (mean age 78)

Comment	Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitivel
Formal Description Interaction-ID: 74161	phenotype decreased level of APOA1 increases_activity of phenotype cognitive decline in a group of Australian patients (mean age 78)

Comment	Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitivel
Formal Description Interaction-ID: 74162	phenotype decreased level of APOA2 increases_activity of phenotype cognitive decline in a group of Australian patients (mean age 78)

Comment	Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitivel
Formal Description Interaction-ID: 74163	phenotype decreased level of APOH increases_activity of phenotype cognitive decline in a group of Australian patients (mean age 78)

Comment	Lower ApoA1, ApoA2 and ApoH levels, and higher ApoB/ApoA1 ratio, increased the risk of cognitive decline over two years in cognitivel
Formal Description Interaction-ID: 74164	phenotype increased level of ApoB/ApoA1 ratio increases_activity of phenotype cognitive decline in a group of Australian patients (mean age 78)

Home
Contact

The Helmholtz Zentrum München Imprint and Privacy Policy apply.

© 2013 - Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH) Ingolstädter Landstraße 1, D-85764 Neuherberg, Germany

Disclaimer: IBIS Databases and associated information are protected by copyright. This server and its associated data and services are for academic, non-commercial use only. The Helmholtz Zentrum München has no liability for the use of results, data or information which have been provided through this server. Neither the use for commercial purposes, nor the redistribution of IBIS database files to third parties nor the distribution of parts of files or derivative products to any third parties is permitted. Commercial users shall contact the Helmholtz Zentrum München for a separate users license.